Cold Weather Could Spell Bad News for Older Residents in Illinois

  • Author: Health Informer
  • Filed under: Health News
  • Date: Dec 11,2008

AARP Encourages Friends, Family, Neighbors to Help Older Neighbors & Launches New Initiative to Help Keep Heating Costs Down

With cold weather hitting Illinois, AARP is reminding friends, family and neighbors to watch out for the well-being of older residents, making sure they’re safe and warm during the winter months. In the face of soaring heating costs, AARP is also encouraging people to join a new initiative aimed at helping residents conserve energy and reduce costs, while still keeping their homes safe and warm for the season.

“Cold weather is a fact of life in Illinois, but it can put many older adults at risk,” said Bob Gallo, AARP Illinois Senior State Director. “Family, friends and neighbors can make a difference by helping older residents to stay warm and safe during winter.”

People can take a number of steps to help make sure older residents are protected from the harsh Illinois winter. Among other things, they should make sure older residents are:

  • Warm and safe indoors and outdoors: Make sure older residents wear warm clothing in several layers. When indoors, stay in a heated room; avoid fire hazards by having proper ventilation when using fireplaces, ood stoves, or space heaters. Functioning smoke and carbon monoxide detectors should be installed.
  • In good health: Make sure older adults continue their exercise regimens, but avoid overly strenuous physical activity; and maintain a healthy diet with plenty of liquids. Caregivers should make sure older adults get vaccinated against the flu and pneumonia.
  • Able to go out safely when needed: Walkways and driveways should be free from snow and ice.
  • Prepared for emergencies: Keep a phone with emergency numbers already pre-entered; and make sure older persons have a personal emergency response system available.

AARP recently launched Operation Energy Save, a new initiative to encourage residents to conserve energy by making small changes around the house to reduce costs. Operation Energy Save features easy-to-use checklists, instructional guides and simple tips to help residents save on energy expenses. The free resource is available at http://www.aarp.org/CreateTheGood.

Older Illinoisans on fixed incomes tend to be hit especially hard by increases to home heating costs — while they use about the same amount of energy as younger people, they spend twice as much to heat their homes. One out of every four low-income older persons spends 19% or more of their total income on home energy bills. A recent, nationwide AARP survey found that 22 percent of Americans are worried about being able to afford their home energy costs this winter.

To help with soaring home heating costs, eligible low-income residents, especially the elderly, can enroll in Illinois’ Low-Income Home Energy Assistance Program (LIHEAP). LIHEAP provides a one-time benefit to eligible households for energy bills on a first come, first serve basis. To learn more, call 1-877-411-WARM (9276) or visit www.liheapillinois.com.

Source: AARP Illinois


New World Cancer Report Released by IARC; U.S. Groups List Six Critical Steps the New U.S. Administration Can Take

Despite the recent good news that cancer incidence and death rates for men and women in the United States continue to decline, cancer is projected to become the leading cause of death worldwide in the year 2010, and low- and middle-income countries will feel the impact of higher cancer incidence and death rates more sharply than industrialized countries. The nation’s leading cancer organizations joined forces today at an event called Conquering Cancer: A Global Effort, to focus attention on the growing global cancer burden and discuss efforts needed to address the problem. The International Agency for Research on Cancer (IARC) released the new edition of the World Cancer Report. The American Cancer Society, the Lance Armstrong Foundation, and Susan G. Komen for the Cure discussed how each organization is addressing the global cancer problem and together issued a call to action for the incoming United States presidential administration and Congress. In addition, a new international documentary film entitled “Cancer Is…” was premiered.

According to the new report, the burden of cancer doubled globally between 1975 and 2000. It is estimated that it will double again by 2020 and nearly triple by 2030. This translates to far greater numbers of people living with – and dying from – the disease. The report estimates that there were some 12 million new cancer diagnoses worldwide this year, and more than seven million people will die from the disease. The projected numbers for the year 2030 are 20-26 million new diagnoses and 13-17 million deaths.

The growing cancer burden includes global increases of incidence of about one percent each year, with larger increases in China, Russia, and India. Reasons for the increased rates include adoption of Western habits in less developed countries, such as tobacco use and higher-fat diets, and demographic changes, including a projected population increase of 38 percent in less developed countries between 2008 and 2030.

In addition to increases in cancer incidence and death rates, the report identifies challenges in cancer care, especially in Africa, where pain management and palliative care are very limited because any use of narcotics is prohibited by law in several countries.

Sharing the stage were John R. Seffrin, Ph.D., chief executive officer, American Cancer Society; Lance Armstrong, founder and chairman, Lance Armstrong Foundation; Hala Moddelmog, president and chief executive officer, Susan G. Komen for the Cure; Peter Boyle, B.Sc., Ph.D., D.Sc.(Med), director, International Agency for Research on Cancer; Alejandro Mohar Betancourt, M.D., Sc.D., director, National Cancer Institute of Mexico, and Bill Gregory, a throat cancer survivor.

The American Cancer Society’s Seffrin said, “For all of our 95 years the Society has pursued the vow of our founders to eliminate cancer in all humankind. We recognize that cancer strikes without regard to borders or socioeconomic status, and we support cancer control initiatives in more than 20 countries, and fund capacity building and tobacco control grants in some 70 countries – including the launch next week of our tobacco Quitline(R) in India. It is my hope that by bringing proven interventions to places in the world impacted most by this disease, we can diminish needless suffering and save many lives.”

Armstrong explained his foundation’s international work, saying, “Since announcing the launch of our international cancer awareness campaign at the Clinton Global Initiative less than three months ago, we are already in discussions with more than 20 nations, NGOs and business leaders to advance this issue. Even in a challenging economy, people realize that with cancer there is progress to be made and prevention measures to be taken.”

“Breast cancer alone will be diagnosed in 25 million women over the next 25 years. Susan G. Komen for the Cure already has changed the way we talk about and treat breast cancer in the United States, and we’re bringing what we’ve learned to developing countries in Asia, Africa, Latin America, the Middle East and Eastern Europe. This ‘global health diplomacy’ approach, with its focus on better access to care, is already educating and empowering women worldwide, and it is critical if we’re to save lives and resolve the growing global cancer crisis,” said Hala Moddelmog, president and CEO of Susan G. Komen for the Cure.

Explaining the results of the report, Dr. Boyle said, “The rapid increase in the global cancer burden represents a real challenge for health systems worldwide. However, there is a clear message of hope: although cancer is a devastating disease, it is largely preventable. We know that preventive measures such as tobacco control, reduction of alcohol consumption, increased physical activity, vaccinations for hepatitis B and human papillomavirus (HPV), and screening and awareness could have a great impact on reducing the global cancer burden.”

“We appreciate the opportunity to stand with leading cancer organizations in the United States to make global cancer a priority. In Mexico, we have seen the power of the government working with the NGO’s, and look forward to collaborating globally to conquer cancer,” said Dr. Mohar of Mexico’s National Cancer Institute.

The six call to action steps issued by the three U.S. organizations include: 1) making vaccines that prevent cancer causing infections more widely available to low-income nations, including specifically combating cervical cancer through Global Alliance for Vaccines and Immunizations (GAVI) efforts to make the HPV vaccine accessible and affordable; 2) committing to a comprehensive tobacco control approach in the U.S., which includes taking measures proven effective in reducing smoking rates and having Congress grant the Food and Drug Administration (FDA) authority to regulate tobacco; 3) ratifying immediately the Framework Convention on Tobacco Control (FCTC), the first ever global public health treaty that sets forth comprehensive measures to reduce health and economic impacts of tobacco; 4) supporting efforts of non-governmental organizations to build advocacy and resources, empower survivors and reduce suffering in low- to middle-income countries by working with governments, medical professionals and the corporate sector to enable individuals to adopt healthier behaviors; 5) promoting culturally sensitive risk reduction and education campaigns by leveraging our own successful U.S. efforts to help build capacity of nongovernmental organizations in other countries; and 6) investing in cancer research and expanding access to prevention and early detection measures in the U.S., with a specific focus on increasing federal funding of medical research.

The news conference also featured the domestic launch of a new documentary film series focused on the global cancer problem titled “Cancer Is…” The documentary is narrated by former U.S. President George H. W. Bush, and was produced by France’s Cemil Alyanak, a renowned expert on global health communications.

American Cancer Society

The American Cancer Society is dedicated to eliminating cancer as a major health problem by saving lives, diminishing suffering and preventing cancer through research, education, advocacy and service. Founded in 1913 and with national headquarters in Atlanta, the Society has 13 regional Divisions and local offices in 3,400 communities, involving millions of volunteers across the United States. For more information on our global programs, visit www.cancer.org/international.

Lance Armstrong Foundation

At the Lance Armstrong Foundation, we stand up for the 25 million people around the world living with cancer today. There can be – and should be – life after cancer for more people. That’s why we work to prevent cancer, ensure patients get proper cancer screening and care, support research and help cancer survivors live life on their own terms. We kick in at the moment of diagnosis, giving people the support they need to fight cancer head-on. We find creative ways to raise awareness and end the stigma about cancer that many survivors face. We connect people and communities to drive social change, and we call for state, national and world leaders to help fight this disease. Join us at LIVESTRONG.org.

Susan G. Komen for the Cure

Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure and launched the global breast cancer movement. Today, Komen for the Cure is the world’s largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure(R), we have invested more than $1.2 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world. For more information about Susan G. Komen for the Cure, breast health or breast cancer, visit www.komen.org or call 1-877 GO KOMEN.

International Agency for Research on Cancer

The International Agency for Research on Cancer (IARC) is part of the World Health Organization. IARC’s mission is to coordinate and conduct research on the causes of human cancer, the mechanisms of carcinogenesis, and to develop scientific strategies for cancer control. The Genetic Epidemiology Group within IARC conducts large scale case-control studies of specific cancers, and participates in international consortia, in order to ensure that studies have adequate sample size.

Source: American Cancer Society


US Oncology Affiliated Physicians Participate in ASH Conference

A leading cancer researcher affiliated with the US Oncology Research Network will present findings from a randomized, multicenter Phase III trial that compared FCR and PCR in patients with B-cell chronic lymphocytic leukemia (CLL).

The study results will be given in an oral presentation by Dr. Craig Reynolds of Ocala Oncology Center at the 50th Annual Meeting of the American Society of Hematology (ASH) held December 6-9, 2008 in San Francisco. Dr. Reynolds is the lead investigator and serves as co-chairman, and chairman for new protocol development, of US Oncology’s National Lung Cancer Research Committee.

Purine analog-based regimens have emerged as highly active regimens in the treatment of chronic lymphocytic lymphoma (CLL). Promising results have been reported with the combination of fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) by Keating and colleagues at the University of Texas M.D. Anderson Cancer Center. Previous US Oncology Research Network, as well as a Mayo Clinic and MSKCC trials, evaluated the combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR); results suggested similar efficacy with less infectious complications than that seen with FCR.

The current multicenter, randomized, community-based trial was conducted to compare FCR and PCR in previously untreated or minimally treated B-cell chronic lymphocytic leukemia. The primary end point of the study was infectious complications with efficacy and safety as secondary endpoints. Correlative studies of immune function were conducted by Kay and colleagues at the Mayo Clinic and will be reported separately.

“This study establishes the role of these regimens in the treatment of CCL,” said Dr. Reynolds. “New therapies such as these offer hope for our patients.”

The research found that both PCR and FCR have significant activity in CLL and can be given safely in the community setting. Both regimens possess significant toxicity and response rates in this multi-institution, community-based randomized trial were lower than previous Phase II trials of previously untreated patients. This trial did not demonstrate a lower infection rate with PCR using pentostatin at the 4 mg/m2 dose level. In early follow-up, no statistically significant differences with respect to overall response rate or survival were observed between FCR and PCR, although the CR rate was significantly higher with FCR.

This research will be presented at the 50th Annual Meeting of the American Society of Hematology on December 8, 2008 at 11:30 a.m. PST.

Physician researchers affiliated with the US Oncology network will also present the following US Oncology Research network studies as posters at this year’s ASH conference:

  • Nicholas Di Bella, M.D., Rocky Mountain Cancer Centers-Parker: Results of a Phase II study of Bortezomib in patients with relapsed or refractory indolent lymphoma
  • Robert Rifkin, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II open label-trial of Bortezomib in patients with multiple myeloma who have undergone high-dose melphalan therapy followed by autologous peripheral blood stem cell transplantation and failed to achieve a complete response.

The following physicians affiliated with the US Oncology network participated in the following studies that will be presented as oral and poster presentations and published studies at this year’s ASH conference:

Acute Myeloid Leukemia (AML)

  • Roger Lyons, M.D., Cancer Care Centers of South Texas-Medical Center: Phase II study of single agent Clofarabine in previously untreated older adult patients with acute myelogeneous leukemia (AML)  unlikely to benefit from standard induction chemotherapy
  • Michael Maris, M.D., M.D., Rocky Mountain Cancer Centers-Midtown: Phase II study of Voreloxin (formerly known as SNS-595) as single agent therapy for elderly patients with newly diagnosed acute myeloid leukemia (AML): preliminary safety and clinical responses (The REVEAL-1 study)

Hematologic Malignancies

  • Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Superiority of Rasuburicase vs. Allopurinol on serum uric acid control in adult patients with hematologic malignancies at risk of developing Tumor Lysis Syndrome

Multiple Myeloma

  • Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II study of oral Panobinostat in adult patients with advanced refractory multiple myeloma

Waldenstrom Macroglobulinemia

  • Jeffrey Matous, M.D., Rocky Mountain Cancer Centers-Midtown: Phase II trial of combination of Bortezomib and Rituximab in relapsed and/or refractory Waldenstrom Macroblobulinemia; Long-term responses to Fludarabine and Rituximab in Waldenstrom Macroblobulinemia

Chronic Lymphocytic Leukemia

  • Jeff Sharman, M.D., Willamette Valley Cancer Center-Springfield: Fostamatinib Disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B-cell lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (CLL)

US Oncology Research

The US Oncology Research network is an established community-based research operation specializing in comprehensive Phase I-IV trials and translational Phase I research. The research network is currently enrolling patients at 109 research sites, and is involved in 63 open trials.

Supported by US Oncology, the network has played a pivotal role in 24 of the last 30 cancer drugs approved by the Food and Drug Administration and more than 32,000 patients have participated in clinical trials. For more information, visit the “Research” section under “Our Services” on the company’s Web site, www.usoncology.com.

US Oncology

US Oncology, headquartered in Houston, works closely with physicians, manufacturers and payers to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation’s foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology’s expertise in supporting every aspect of the cancer care delivery system–from drug development to treatment and outcomes measurement, enables the company to help increase the efficiency and safety of cancer care. According to the company’s last quarterly earnings report, US Oncology is affiliated with 1,227 physicians operating in 485 locations, including 92 radiation oncology facilities in 39 states. For more information, visit the company’s Web site, www.usoncology.com.


86 Percent of Patients With Ph+ Chronic Myeloid Leukaemia Treated With Breakthrough Treatment Glivec(R) are Alive After Seven Years(1)

  • Treatment Shown to Slow Disease Progression: Only one Patient out of 317 Experienced Disease Progression Between Year Six and Seven of Treatment(1)
  • Data Demonstrate Longest Overall Survival Observed to Date in This Disease Area

Nearly nine out of ten patients (86 percent) with a life-threatening leukaemia are still alive seven years after diagnosis when treated with Glivec (imatinib). Data from the largest clinical trial in newly diagnosed patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) demonstrate the longest overall survival observed to date in this disease area.

Data presented today from the 7-year update of the landmark International Randomized Interferon versus STI571 (IRIS) study also demonstrate an extremely low rate of disease progression. Between years six and seven, only one patient progressed to a more advanced stage of the disease.(1)

CML, one of the most common leukaemias, is a progressive disease. Patients are usually diagnosed in the chronic phase of the disease and then progress through several stages before eventually reaching the final blast crisis phase. Before Glivec’s availability in 2001, almost 60 percent of patients treated with interferon alpha (the previous standard treatment for CML) would not survive to five years.(2),(3) Once patients reached the blast crisis stage of the disease, survival was generally limited to only three to six months.(4)

Dr Stephen O’Brien, Senior Lecturer in Experimental Haematology, University of Newcastle, and investigator on the IRIS trial said: “CML patients treated with imatinib continue to demonstrate impressive long-term survival. Long-term analyses are offering important new insights and, encouragingly, we’re seeing that patients’ clinical responses are durable over time.”

Lead investigators presented the updated findings from the study involving more than 1,100 newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) at the 50th Annual Meeting of the American Society of Haematology (ASH).

Sandy Craine, the first person in Europe to be treated with Glivec, and founder of The CML Support Group in the UK said: “Glivec has had an incredible impact on patients. Without this treatment many people with CML would not be alive today. Glivec certainly helped to save my life and it is more than encouraging that so many more people are now able to tell the same story of living long term, probably their natural life span, with what once was a terminal disease.”

CML is one of the four most common leukaemias in the world affecting 4000 people in the UK, with around 800 new cases being diagnosed each year.(5) It is the result of an abnormal chromosome which is involved in controlling the production of white blood cells.

References

1. O’Brien S, et al. International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up Sustained survival, low rate of  transformation and increased rate of major molecular response in  patients with newly diagnosed chronic myeloid leukemia in chronic  phase treated with imatinib. Abstract # 186. American Society of  Haematology 2008 Annual Meeting, San Francisco, CA.

2. O’Brien SG, Guilhot F, Larson RA et al. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase  Chronic Myeloid Leukemia. N Engl J Med 2003;348:994-1004

3. Chronic Myeloid Leukaemia Trialists’ Collaborative Group. J Nat Can Inst. 1997;89(21):1616-1620

4. Guidance on the use of imatinib for CML, NICE technology Appraisal 70, October 2003

5. CancerBackup, Nice one – CancerBACUP welcomes decision on treatment for leukaemia

http://www.cancerbackup.org.uk/News/Mediacentre/Pressreleasesstatements/2002/4352

Last accessed 1 December 2008

6. Faderl S; Talpaz M; Estrov Z; O’Brien S; Kurzrock R; Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 341:164-72,  1999.

About The International Randomized Interferon versus STI571 (IRIS) Study

IRIS is an open-label Phase III clinical trial enrolling 1,106 newly diagnosed patients with chronic phase Ph+ CML in 177 centres across 16 countries. There are two arms to the study: one group of patients received Glivec 400 mg per day, while the other received a target dose of interferon (IFN) of 5 MIU/m2/day in combination with cytarabine (Ara-C) 20 mg/m2/day for 10 days each month. Because of tolerability issues, lack of response or loss of response, 65% of patients in the IFN/Ara-C arm crossed over to the Glivec arm, whereas only 3% of patients in the Glivec arm crossed over to the IFN/Ara-C arm.

In IRIS, treatment with Glivec was well-tolerated. No new safety issues were identified between the sixth and seventh years of treatment(1).

Glivec

Glivec is approved in more than 90 countries including the US, EU and Japan for the treatment of all phases of Ph+ CML. Glivec is also approved in the EU, US and other countries for the treatment of patients with Kit (CD117)-positive gastrointestinal tumours (GIST), which cannot be surgically removed and/or have already spread to other parts of the body (metastasised). In Japan, Glivec is approved for the treatment of patients with Kit (CD117)-positive GIST. In the EU, Glivec is also approved for the treatment of adult patients with newly diagnosed Ph+ acute lymphoblastic leukaemia (Ph+ ALL) in combination with chemotherapy and as a single agent for patients with relapsed or refractory Ph+ ALL. Glivec is also approved for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) who are not eligible for surgery. Glivec is also approved for the treatment of patients with myelodysplastic/myeloproliferative diseases (MDS/MPD). Glivec is also approved for hypereosinophilic syndrome and/or chronic eosinophilic leukaemia (HES/CEL).

The effectiveness of Glivec is based on overall haematologic and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, and on objective response rates in GIST and DFSP. There are no controlled trials demonstrating increased survival.

Not all indications are available in every country.

About chronic myeloid leukaemia

Chronic myeloid leukaemia (CML) is an abnormality of white blood cell production. CML one of the four most common types of leukaemia affecting approximately 4,000 people in the UK.5 It is the result of a genetic abnormality called the Philadelphia chromosome (Ph+) which is found in up to 95 per cent of patients with CML.(6) There are 800 new cases of CML diagnosed in the UK each year and it accounts for 15 percent of leukaemias in adults.(5),(6) The median age of patients is between 45 to 55 years old, but CML can affect people of all ages.(6)

Most people with CML have the Philadelphia chromosome, which can be detected by laboratory tests. In CML, when the cells divide, part of chromosome 9 (the ABL gene) wrongly moves over to join chromosome 22 where the BCR gene sits. The resulting abnormality is known as Bcr-Abl.(6) The protein (tyrosine kinase) produced by Bcr-Abl stimulates the production of white blood cells by the bone marrow, prevents the white blood cells from maturing and encourages CML cells to divide. Patients with CML are prone to repeated infections because they cannot produce enough normal white blood cells to mount an effective immune response.

About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and society. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in each of these areas. In 2007, the Group’s continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 97,000 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.